New paper published: Comparative effectiveness of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) in children over multiple influenza seasons (2019–2023)

Abstract Vaccine effectiveness (VE) of quadrivalent live attenuated influenza vaccine (LAIV4) and quadrivalent inactivated influenza vaccine (IIV4) in children in 13 European countries and the US during the 2019–2023 influenza seasons was evaluated from published literature, congress presentations, public health websites, and personal communications with investigators.A meta-analysis was performed by assessing LAIV4 and/or IIV4 VE…

The influenza landscape and vaccination coverage in older adults during the SARS-Cov-2 pandemic: data from Several European Countries and Israel

ABSTRACT Introduction: The Raise Awareness of Influenza Strategies in Europe (RAISE) group gathered information about the healthcare burden of influenza (hospitalizations, intensive care unit [ICU] admissions, and excess deaths), surveillance systems, and the vaccine coverage rate (VCR) in older adults in 18 European countries and Israel. Areas covered: Published medical literature and official medical documentation…

Yellow fever – African Region (AFRO)

Situation at a Glance Since the beginning of 2023, and as of 25 February 2024, a total of 13 countries in the WHO African Region have documented probable and confirmed cases of yellow fever (YF), namely Burkina Faso, Cameroon, the Central African Republic, Chad, Republic of the Congo, Côte d’Ivoire, the Democratic Republic of the…

NECTM9 – Early Bird Deadline March 3rd 2024

The NECTM9 conference in Copenhagen is fast approaching. Don’t forget to register to NECTM9 before early bird expires March 3rd. Click here to see the registration fees and register for the conference using the button below. Industry Symposium At NECTM9 there will be six symposiums sponsored by the industry. The industry symposiums are located during breakfast, lunch or…